Incidence of obesity and diabetes is rising in India, the world's most populous country, which also ranks among the worst ...

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

Demand for weight-loss drugs is rising at a fast clip in India where rivals Eli Lilly and Novo Nordisk are competing for ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

The country’s Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, the UK’s official system for ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

Retirees looking for dividend growth stocks at a reasonable price have ample reasons to look outside of America, especially ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.